Management of Raynaud's phenomenon in systemic sclerosis-a practical approach.
Ontology highlight
ABSTRACT: Raynaud's phenomenon is nearly universal in systemic sclerosis. Vasculopathy is part of systemic sclerosis. Raynaud's phenomenon can cause of complications and impairment, especially when tissue ischemia and digital ulcers develop. There are many treatment options for Raynaud's phenomenon in systemic sclerosis often with sparse data and few robust studies comparing the different treatment options. Recommendations from guidelines usually include calcium channel blockers as first-line pharmacological treatment. In the clinical setting, multiple variables such as financial factors, geography where access to medications varies, and patient factors, baseline hypotension, can influence the treatment for Raynaud's phenomenon and digital ulcers. Prostacyclins and PDE-5 inhibitors are reserved for
SUBMITTER: Fernandez-Codina A
PROVIDER: S-EPMC8922649 | biostudies-literature | 2019 Jun
REPOSITORIES: biostudies-literature
ACCESS DATA